Navigation Links
Sequenom Appoints Two New Board Members
Date:12/16/2009

SAN DIEGO, Dec. 16 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM), today announced the appointment of Dr. Kenneth Buechler and Mr. David Pendarvis to its board of directors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)

Kenneth F. Buechler, Ph.D., was president, chief scientific officer and co-founder of Biosite Incorporated. From 1988 to 1994, Dr. Buechler was Biosite's director of chemistry. Prior to forming Biosite, Dr. Buechler was a senior research scientist for the diagnostics research and development group at Hybritech Incorporated in San Diego. Dr. Buechler received his doctorate in biochemistry and his bachelor's degree in chemistry from Indiana University. Dr. Buechler sits on the boards of Quidel Corp., Sotera Wireless Inc., Adnavance Inc., and Astute Medical Inc.

David Pendarvis is senior vice president - organizational development, global general counsel and secretary of ResMed Inc., a medical device company focused on sleep-disordered breathing. He has been with ResMed since 2002. From 2000 until 2002, Mr. Pendarvis was a partner in the law firm of Gray Cary Ware & Freidenrich LLP. Until 2000 he was a partner with Gibson, Dunn & Crutcher LLP, where he began working in 1986. From 1984 until 1986 he was a law clerk to the Hon. J. Lawrence Irving, US District Judge, Southern District of California. Mr. Pendarvis received his J.D. from the University of Texas School of Law, a MS in executive leadership from the University of San Diego, and a BA from Rice University.

"I am delighted that Ken and David have agreed to join our board of directors," said Dr. Harry Hixson, interim chief executive officer at Sequenom. "The talent and diverse expertise of our board has always been one of Sequenom's assets. With their proven industry executive experience, Ken and David are key additions to our team."

Dr. Buechler and Mr. Pendarvis join existing board members Dr. Ernst-Gunter Afting, Dr. Charles Cantor, Mr. John Fazio, Dr. Harry Hixson, Dr. Richard Lerner, Dr. Ronald Lindsay and Ms. Kathleen Wiltsey.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

SEQUENOM(®) is a registered trademark of Sequenom, Inc.

SOURCE Sequenom, Inc.


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24
2. Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3
3. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
4. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
5. SEQUENOM Announces Launch of MassARRAY Compact 96 System
6. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
7. SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia
8. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
9. Codexis Appoints Singapore Laboratories Managing Director
10. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
Breaking Biology Technology:
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
Breaking Biology News(10 mins):